OK Biotech (4155) Stock Overview
Develops, manufactures, markets, and sells blood glucose monitoring devices and related homecare medical products in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
4155 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
OK Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$14.10 |
| 52 Week High | NT$24.20 |
| 52 Week Low | NT$13.90 |
| Beta | 0.11 |
| 1 Month Change | -4.41% |
| 3 Month Change | -10.76% |
| 1 Year Change | -41.49% |
| 3 Year Change | -39.30% |
| 5 Year Change | -50.67% |
| Change since IPO | 2.04% |
Recent News & Updates
Recent updates
OK Biotech's (TWSE:4155) Earnings Are Of Questionable Quality
Mar 21
OK Biotech's (TWSE:4155) Shareholders Have More To Worry About Than Lackluster Earnings
Aug 20OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend
Apr 26Calculating The Fair Value Of OK Biotech Co., Ltd. (TPE:4155)
Apr 04OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet
Mar 17Has OK Biotech (TPE:4155) Got What It Takes To Become A Multi-Bagger?
Mar 01Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?
Feb 15A Look At OK Biotech's (TPE:4155) Share Price Returns
Jan 31We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide
Jan 17
Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend
Jan 03Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)
Dec 21Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly
Dec 08Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?
Nov 23Shareholder Returns
| 4155 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -2.8% | -2.1% | 2.4% |
| 1Y | -41.5% | -7.4% | 22.0% |
Return vs Industry: 4155 underperformed the TW Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: 4155 underperformed the TW Market which returned 22% over the past year.
Price Volatility
| 4155 volatility | |
|---|---|
| 4155 Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 4155 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4155's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Chia-De Lai | www.okbiotech.com |
OK Biotech Co., Ltd. develops, manufactures, markets, and sells blood glucose monitoring devices and related homecare medical products in Taiwan and internationally. It also provides glucometers and blood glucose test strips; nebulizer, portable nebulizer, mesh nebulizer, and test strips; and personal sound amplifiers. OK Biotech Co., Ltd.
OK Biotech Co., Ltd. Fundamentals Summary
| 4155 fundamental statistics | |
|---|---|
| Market cap | NT$2.00b |
| Earnings (TTM) | -NT$40.68m |
| Revenue (TTM) | NT$1.72b |
Is 4155 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4155 income statement (TTM) | |
|---|---|
| Revenue | NT$1.72b |
| Cost of Revenue | NT$1.38b |
| Gross Profit | NT$338.31m |
| Other Expenses | NT$378.99m |
| Earnings | -NT$40.68m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 19.69% |
| Net Profit Margin | -2.37% |
| Debt/Equity Ratio | 35.2% |
How did 4155 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/01 11:42 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OK Biotech Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yijun Chen | SinoPac Securities Investment Service |